Discover
GRAL
GRAIL, Inc.
45.63
2 x 34.20
2 x 56.79
bid
ask
-
1.93
4.06%
2 @ 04:00 PM
45.60 -0.03 (0.07%)
| Ytd | -46.69% | |
| 1y | 100.57% |
44.06
day range
47.87
22.75
52 week range
116.06
| Open | 46.72 | Prev Close | 47.56 | Low | 44.06 | High | 47.87 | Mkt Cap | 1.87B |
| Vol | 1.29M | Avg Vol | 1.33M | EPS | -11.11 | P/E | N/A | Forward P/E | -5.26 |
| Beta | N/A | Short Ratio | 2.85 | Inst. Own | 74.50% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-12 | 50-d Avg | 65.94 | 200-d Avg | 66.23 | 1yr Est | 72.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-12 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-02-19 | 2025-12 | 0 | N/A | 0.89 | 26.73% |
| 2025-11-12 | 2025-09 | 0 | N/A | 0.94 | 27.65% |
| 2025-11-12 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | -0.04 | -1.27% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-10 | Mizuho | Upgrade | Neutral | |
| 2026-04-10 | Piper Sandler | Upgrade | Neutral | |
| 2026-03-30 | Guggenheim | Upgrade | Buy | Buy |
| 2026-02-24 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2026-02-20 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-02-20 | Baird | Upgrade | Outperform | Outperform |
Profile
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-01-14 | CHASE WILLIAM J | Director | 36.80K | Stock Award(Grant) |
| 2025-06-30 | DING CHUN R | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-04-07 | FREIDIN AARON | Chief Financial Officer | 260.67K | Sale |
| 2025-11-16 | ILLUMINA INC | Beneficial Owner of more than 10% of a Class of Security | 3.50M | Sale |
| 2025-05-28 | KREVANS SARAH | Director | 37.14K | Stock Award(Grant) |
| 2026-01-14 | MIZELL STEVEN CRAIG | Director | 36.67K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Blackrock Inc. | 2.96M | 134.98M | 7.21% |
| 2025-12-30 | Farallon Capital Management LLC | 2.34M | 106.90M | 5.71% |
| 2025-12-30 | Baker Bros. Advisors, LP | 2.09M | 95.15M | 5.08% |
| 2025-12-30 | Vanguard Group Inc | 1.98M | 90.38M | 4.83% |
| 2025-12-30 | Primecap Management Company | 1.84M | 83.90M | 4.48% |
| 2025-12-30 | State Street Corporation | 1.83M | 83.39M | 4.46% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-01-30 | PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 1.31M | 59.72M | 3.19% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.05M | 47.86M | 2.56% |
| 2026-02-27 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.03M | 46.83M | 2.50% |
| 2026-01-30 | iShares Trust-iShares Russell 2000 ETF | 836.79K | 38.18M | 2.04% |
| 2026-01-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 340.34K | 15.53M | 0.83% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 319.62K | 14.58M | 0.78% |
